ABSTRACT
INTRODUCTION: Salidroside (SAL), extracted from Rhodiola rosea, has been widely used in coronary heart disease and myocardial ischemia for decades. Previous studies have demonstrated that SAL could reduce arteriosclerosis, and thus combat ischemic brain damage. However, the in-depth function of the salidroside in Cerebral Small Vascular Disease (CSVD) has not been discovered, and related molecular mechanism is still unclear. OBJECTIVES: The present study aims to explore the effects of salidroside in angiogenesis as well as repair of blood brain barrier (BBB) and its possible mechanisms. METHODS: We established a rat model of SHR via 2-vessel gradual occlusion (SHR-2VGO) to mimic the CSVD. Subsequently, the MRI, pathomorphism, as well as Morriss water maze test were conducted to determine CSVD-related indicators. 8 weeks post-surgery, animals were randomly administered SAL, DAPT, ATN161 or saline.The aim was to explore the protective effects of SAL in CSVD as well as its possible mechanism. RESULTS: Here we found that SAL could attenuate cerebral hypoperfusion-induced BBB disruption, promote the pro-angiogenesis through enhancing the cell budding. Further investigations demonstrated that SAL could significantly increase the expression of Notch1, Hes1, Hes5, and ITGB1. In addition, we confirmed that SAL could activate Notch signal path, and then up-regulate ITGB1 to promote pro-angiogenesis and thus protect BBB from disruption. CONCLUSION: The aforementioned findings demonstrated that SAL could protect BBB integrity through Notch-ITGB1 signaling path in CSVD, which indicated that SAL could be a potential medicine candidate for CSVD treatment.
ABSTRACT
Objective To design a scientific, standardized, fully functional, easy-to-use Guillain-Barré syndrome (GBS) clinical informatization management system, with the purpose to meet the needs of diagnosis and clinical research in patients with GBS. This system can manage and excavate clinical data and provide a platform for clinical research of GBS. Methods The clinical data items of GBS were identified. The Visual Basic 6.0 and Vista DB software development environment was used to develop the system and the related database based on embedded database. Results A GBS database including 560 clinical indicators were set up. Through the built-in data mining and analysis functions, the system can realize the functions of visualized data input, combination search, statistical analysis, data exchange and literature update. This system has been used in Xijing Hospital, and a total 274 clinical and prognostic records were recorded from the patients with GBS. The practical results proved that the system can achieve the design goals. Conclusions Based on the information technology and GBS-related clinical epidemiology and neurology expertise, a standard GBS clinical data management and analysis system and related database were established, which could provide a basis for GBS information storage, update, epidemiological investigation and prognosis.
ABSTRACT
Objective To study the effect of blood coagulation function and nerve function of beraprost in the treatment of acute cerebral infarction.Methods 80 cases of acute cerebral infarction were randomly divided into 2 groups, 40 cases in the control group and 40 cases in the experiment group.The control group received routine treatment, the experiment group were treated with the same as the control group combined with beraprost.Changes of coagulation function and nerve function were compared pre-and post-treatment between two groups.Results Compared with pre-treatment, APTT, PT, Fib level, serum NGF level, Barthel score increased post-treatment of the two groups, D-D, serum NSE, S100b, NIHSS score decreased, compared with the control group, APTT, PT, Fib level, serum NGF level, Barthel score were higher in the experiment group, the total effective rate was higher than the control group, two D-D, serum NSE, S100β, NIHSS scores were lower than the control group, the differences were statistically significant (P<0.05).Conclusion Beraprost can reduce the high coagulation state in patients with acute cerebral infarction, improve the degree of neurological impairment, and has good clinical efficacy.